Last reviewed · How we verify
XEN1101
XEN1101 is a selective Nav1.7 sodium channel blocker.
XEN1101 is a selective Nav1.7 sodium channel blocker. Used for Treatment of trigeminal neuralgia.
At a glance
| Generic name | XEN1101 |
|---|---|
| Also known as | Azetukalner |
| Sponsor | Xenon Pharmaceuticals Inc. |
| Drug class | sodium channel blocker |
| Target | Nav1.7 |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | Phase 3 |
Mechanism of action
By blocking the Nav1.7 sodium channel, XEN1101 is intended to reduce pain by inhibiting the transmission of pain signals in the nervous system.
Approved indications
- Treatment of trigeminal neuralgia
Common side effects
- Dizziness
- Nausea
- Headache
Key clinical trials
- A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (PHASE3)
- A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures (PHASE3)
- A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) (PHASE3)
- An Open-label Study of XEN1101 in Epilepsy (PHASE3)
- An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE) (PHASE3)
- An Open-Label Study of Azetukalner in Major Depressive Disorder (PHASE3)
- A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) (PHASE3)
- A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XEN1101 CI brief — competitive landscape report
- XEN1101 updates RSS · CI watch RSS
- Xenon Pharmaceuticals Inc. portfolio CI